H3K18 lactylation drives CD8+ T cell exclusion and anti-PD-1 resistance in hepatocellular carcinoma
Cell Reports · 2026-08 · 45 (8) · 117761
DOI: 10.1016/j.celrep.2026.117761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-08. Verfasst von Jiang Zhu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Breast Center, West China Hospital, Sichuan University…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, West China Hospital of Sichuan University, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
Glycolytic metabolism promotes an immunosuppressive microenvironment in HCC, but its role in immunotherapy resistance is unclear. Patients with HCC with high 18F-FDG uptake on PET/CT show reduced anti-PD-1 response. High glycolysis-driven H3K18la levels correlate with immunotherapy resistance, limited CD8+ T cell infiltration, and poor prognosis. Inhibiting H3K18la suppresses HCC progression and enhances CD8+ T cell antitumor immunity. Mechanistically, H3K18la increases chromatin accessibility at TRPS1 and ETV1 promoters, upregulating their transcription. TRPS1 reinforces glycolysis and GLUT1-mediated resistance to CD8+ T cell bystander killing, while ETV1-driven CCL2 creates an immunosuppressive niche limiting CD8+ T cell accumulation. Triple combination of the GLUT1 inhibitor BAY-876, anti-CCL2 antibody, and anti-PD-1 antibody potentiates CD8+ T cell antitumor immunity. The H3K18la-TRPS1/ETV1-GLUT1/CCL2 axis serves as a biomarker for immunotherapy resistance, and disrupting this axis sensitizes HCC to immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Breast Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Hepatic AI Translation, Frontie…
- Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Liver Transplant Center, Transplant Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of He…
- Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; Breast Center, West China Hospital, Sichuan University, Chengdu 610041, China; Institute of Breast Health Medicine, Frontier…
- Laboratory of Hepatic AI Translation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
- Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Intervention Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Förderung
- National Natural Science Foundation of China
- West China Hospital of Sichuan University
- National Major Science and Technology Projects of China
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Zhu, J., Dai, X., Luo, T., Zhou, Q., Feng, X., Liu, C., Zhang, B., Yin, B., Wu, P., Luo, R., Gao, F., Jing, J., Xie, K., Lan, T., & Wu, H. (2026). H3K18 lactylation drives CD8+ T cell exclusion and anti-PD-1 resistance in hepatocellular carcinoma. Cell Reports, 45(8), 117761. https://doi.org/10.1016/j.celrep.2026.117761
Vancouver
Zhu J, Dai X, Luo T, Zhou Q, Feng X, Liu C, et al. H3K18 lactylation drives CD8+ T cell exclusion and anti-PD-1 resistance in hepatocellular carcinoma. Cell Reports. 2026;45(8):117761. doi:10.1016/j.celrep.2026.117761
BibTeX
@article{Zhu2026,
author = {Zhu, Jiang and Dai, Xinye and Luo, Ting and Zhou, Qingbo and Feng, Xuping and Liu, Chang and Zhang, Buzhe and Yin, Bangjie and Wu, Pu and Luo, Ruihan and Gao, Fengwei and Jing, Jing and Xie, Kunlin and Lan, Tian and Wu, Hong},
title = {H3K18 lactylation drives CD8+ T cell exclusion and anti-PD-1 resistance in hepatocellular carcinoma},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {8},
pages = {117761},
doi = {10.1016/j.celrep.2026.117761}
}
EUVIMED